Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS South Australia Inc

Registered Charity 3104


Mailing address:

PO Box 322,
Modbury North,
South Australia 5092

1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.


ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (Word, 198 KB)
Why become a member?

Study Assesses Economic Burden Of Fibromyalgia In The US

Wednesday 17 June 2015


From Fibromyalgia News Today:


Judy Mikovits

Study Assesses Economic Burden of Fibromyalgia In The US

By Isaura Santos
June 4th, 2015

A team of scientists recently conducted research to assess the economic burden of those suffering with fibromyalgia and chronic widespread pain (CWP) in the United States. The study, entitled “The Comparative Burden of Chronic Widespread Pain and Fibromyalgia in the United States,“ was published in the Pain Practice journal.

According to the National Fibromyalgia & Chronic Pain [Association], fibromyalgia affects about 10 million people in the United States and between 3 and 6 percent of the world population. Both fibromyalgia and CWP are characterized by abnormal pain processing, widespread pain, sleep disturbance, fatigue and frequent psychological distress.

The study included a multistage, observational evaluation that included an online screening survey of a diverse and extensive geographical sample of the United States to assess CWP status, a physician visit to determine the fibromyalgia diagnosis, and another online questionnaire to register clinical characteristics, health status, pain, sleep, functioning, productivity, healthcare resource use (HRU) and costs. Based on this evaluation, three groups of individuals were identified: subjects without CWP (CWP−) and other with CWP but without FM (CWP+), and a group with confirmed FM.

The disease burden was analyzed in 472 subjects: 125 CWP-; 176 CWP+ and 171 FM. Race, age and ethnicity were identical across all groups. The mean body mass index and the number of comorbidities was higher from CWP− to CWP+ to FM. From CWP− to CWP+ to FM, there was also lower health status and sleep outcomes. Pain severity, overall work impairment (WPAI:SHP) and interference with function (BPI-SF) increased from CWP− to CWP+ to FM. Higher proportions of CWP+ (52.8 percent) and FM subjects (62.6 percent) were taking pain-related prescription medications relative to CWP− subjects (32.8 percent). There were significant differences in both total direct and indirect costs across all 3 groups and the highest costs were identified among fibromyalgia subjects.

Fibromyalgia individuals were characterized by the highest disease burden; more pain-related medications and comorbidities, lower health status, sleep, function and productivity were associated with these patients as well the highest overall healthcare costs.

© BioNews Services 2015.
All rights reserved.


The above originally appeared here.


Arrow right

More Fibromyalgia News



blog comments powered by Disqus
Previous Previous Page